HGHongzhou Gu

Hongzhou Gu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hongzhou Gu has a total of 205 co-authors. Here are the top co-authors by number of shared publications:

  • Chunhai Fan

    Shanghai Jiao Tong University

    9 shared publications
  • Wei Li

    Fudan University Shanghai Cancer Center, and the Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Shanghai Stomatological Hospital, Fudan University, Shanghai 200032, China

    9 shared publications
  • Kai Xia

    Jiaxing Key Laboratory of Biosemiconductors (A) Xiangfu Laboratory Jiashan Zhejiang China

    7 shared publications
  • Xinyu Du

    Key Laboratory of Breast Cancer in Shanghai Department of Breast Surgery and Department of gynecologic oncology Institutes of Biomedical Sciences Fudan University Shanghai Cancer Center Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 China

    6 shared publications
  • Ronald R. Breaker

    Department of Molecular, Cellular and Developmental Biology, Yale University

    5 shared publications
  • Jiangchao Qian

    East China University of Science and Technology

    4 shared publications

Latest Publications

  • Open Access

    Co-engineering DNAzymes and Phagemid Systems for Efficient and Scalable Production of Functional Single-Stranded DNA Nanostructures

    by Jinyi Hu, Wanqing Ding, Ning Jiang, Yujie Wang, Junjun Hou, Hongzhou Gu, Linjie Guo, Lihua Wang, Jiang Li, Jiaofang Huang, et al.

    DNA nanostructures have been widely explored for diverse applications, yet their scalable and cost-efficient production remains a major limitation. Phagemid-based biosynthesis of single-stranded DNA (ssDNA) provides a promising approach, but its efficiency is constrained by limited deoxyribozyme (DNAzyme) performance and suboptimal system design. Here, we develop an optimized bioproduction platform for ssDNA nanostructures by simultaneously engineering DNAzymes and phagemid-based production systems. Sequence-guided DNAzyme design identifies determinants for catalytic efficiency and pH adaptability, enabling highly efficient and robust in cis cleavage. The optimized DNAzymes achieve 100% self-cleavage within 30 min and expand the operational pH range from a narrow window around 7.2 to 6.6–7.8, thus enabling more reliable production of target ssDNA for structural folding. By combining optimization of phagemid constructs and helper phage/plasmid combinations, the resulting platform supports the biotechnological production of different nanostructures, including square and aptamer-functionalized triangle assemblies. With the p3024 phagemid and VCSM13 helper phage, production of functionalized triangular ssDNA nanostructures was successfully scaled to a 5 L bioreactor, yielding 151.0 mg/L phagemid ssDNA. Doxorubicin-loaded, aptamer AS1411-functionalized triangular nanostructures (DOX@DN-AS1411) enabled targeted and rapid intracellular drug delivery in breast cancer cells. This work establishes a scalable platform to produce programmable DNA nanostructures, facilitating their translation toward biomedical and nanomanufacturing applications.

  • Multidimensional Quantitative Analysis of Biological Responses to DNA Nanoassemblies with Defined Structure and Surface Chemistry

    by Xinwei Xia, Xinhua Dai, Yujia Chen, Wenze Xiao, Liman Chen, Hongzhou Gu

    DNA nanoassemblies (DNs) have emerged as programmable platforms for biomedical applications; however, a quantitative understanding of how structure and surface chemistry jointly govern their biological behavior remains limited. Here, we establish a multidimensional analytical framework to systematically quantify structure-surface-function relationships in DNs. Representative DNs with distinct structural architectures, including a one-dimensional rod-like six-helix bundle (6HB), a two-dimensional planar three-point star (3PS), and a three-dimensional tetrahedron (TDN), along with their cholesterol- and PEG20k-modified counterparts, were constructed and comparatively analyzed across serum stability, cellular uptake, inflammatory responses, and in vivo performance. Both structure and surface modification significantly influenced DN behavior. Cholesterol modification generally enhanced cellular uptake across BMDM, HEK293T, and HeLa cells to 1.09 to 3.34 times that of the corresponding unmodified DNs, while reducing serum stability by 44–70% after 24 h of incubation in 20% FBS. In contrast, PEG20k modification increased serum stability by 27–85% and attenuated inflammatory responses. Notably, identical surface modifications produced distinct biological effects across DNs of different structures, supporting a coupled rather than additive interplay between structure and surface chemistry. This work provides a quantitative basis for correlating DN design parameters with biological outcomes and establishes a generalizable analytical framework for matching DN structure and surface chemistry to application-specific biological requirements.

  • Structure‐Guided Redesign of Terminal Deoxynucleotidyl Transferase Enables Scalable Enzymatic DNA Synthesis for Data Storage

    by Yasong Wu, Jiabin Wang, Shaodong Liu, Yang Liu, Xinwei Hou, Jiahui Zhang, Zhiwen Lv, Zejian Wang, Shihua Luo, Hongzhou Gu, et al.

    DNA, with its exceptional information capacity and chemical stability, represents a promising material for next‐generation data storage to meet the exponential growth of global digital information demands. Enzymatic DNA synthesis provides a sustainable route to DNA production. However, the practical scalability of the underlying polymerization chemistry has been fundamentally constrained by the low catalytic efficiency and aggregation‐induced inactivation of terminal deoxynucleotidyl transferase (TdT) that is responsible for nucleotide polymerization. Here, we report a structure‐guided enzyme design framework that overcomes these intrinsic limitations by decoupling solubility and catalytic performance in a processive polymerase. Computational redesign of aggregation‐prone regions markedly enhances soluble expression, while targeted active‐site engineering improves catalytic efficiency toward 3′‐ONH 2 ‐dNTPs used in enzymatic DNA synthesis. The resulting TdT variant HL2‐LKI achieves 3.4 g L −1 soluble expression in a 5 L fermenter without fusion tags and exhibits high polymerization efficiency (99.9%) and DNA writing fidelity (98.9%). This redesign reduces enzyme production costs to approximately $0.7 g −1 , nearly seven orders of magnitude lower than the catalog price of commercially available TdT. This work establishes a generalizable strategy for transforming aggregation‐limited enzymatic polymerization reactions into scalable and low‐cost molecular manufacturing processes, thereby advancing the practical implementation of DNA as an information material.

  • Structure‐Guided Redesign of Terminal Deoxynucleotidyl Transferase Enables Scalable Enzymatic DNA Synthesis for Data Storage

    by Yasong Wu, Jiabin Wang, Shaodong Liu, Yang Liu, Xinwei Hou, Jiahui Zhang, Zhiwen Lv, Zejian Wang, Shihua Luo, Hongzhou Gu, et al.

    DNA, with its exceptional information capacity and chemical stability, represents a promising material for next‐generation data storage to meet the exponential growth of global digital information demands. Enzymatic DNA synthesis provides a sustainable route to DNA production. However, the practical scalability of the underlying polymerization chemistry has been fundamentally constrained by the low catalytic efficiency and aggregation‐induced inactivation of terminal deoxynucleotidyl transferase (TdT) that is responsible for nucleotide polymerization. Here, we report a structure‐guided enzyme design framework that overcomes these intrinsic limitations by decoupling solubility and catalytic performance in a processive polymerase. Computational redesign of aggregation‐prone regions markedly enhances soluble expression, while targeted active‐site engineering improves catalytic efficiency toward 3′‐ONH 2 ‐dNTPs used in enzymatic DNA synthesis. The resulting TdT variant HL2‐LKI achieves 3.4 g L −1 soluble expression in a 5 L fermenter without fusion tags and exhibits high polymerization efficiency (99.9%) and DNA writing fidelity (98.9%). This redesign reduces enzyme production costs to approximately $0.7 g −1 , nearly seven orders of magnitude lower than the catalog price of commercially available TdT. This work establishes a generalizable strategy for transforming aggregation‐limited enzymatic polymerization reactions into scalable and low‐cost molecular manufacturing processes, thereby advancing the practical implementation of DNA as an information material.

  • Open Access

    Generation of HBV cccDNA using single-stranded M13 phage DNA for authentic minichromosome functionality

    by Yumeng Li, Ting Hua, Menghan Hao, Liman Chen, Wenjun Huang, Zhong Fang, Asha Ashuo, Yaming Li, Zhigang Yi, Hongzhou Gu, et al.

    Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) persists as minichromosomes in the nuclei of hepatocytes and serves as the transcriptional template for viral RNAs. The stable cccDNA pool, characterized by a very low copy number, poses challenges for studying its molecular characteristics and developing targeted therapeutics. To accurately mimic the full-length sequences and structure of HBV cccDNA, we developed a novel method using an M13 phage-based system and deoxyribozyme to produce full-length single-stranded DNA (ssDNA) corresponding to both the positive and negative strands of cccDNA. This method involves the cyclization of the ssDNA followed by the addition of T4 DNA ligase, thereby producing the cccDNA. The in vitro cyclized cccDNA, formed by M13 phage-derived single-stranded DNA (McccDNA), allows the formation of minichromosomes in transiently transfected hepatic cells, recapitulates key stages of the HBV life cycle, and effectively responds to multiple antiviral drugs. Additionally, McccDNA, as it contains no exogenous sequences, was shown to accurately transcribe major viral RNAs and organize nucleosomes in a sequence-specific manner. Furthermore, the McccDNA model allows for targeted deletion of viral proteins, producing a loss-of-function phenotype useful for further minichromosome studies. In conclusion, McccDNA generated from single-stranded M13 phage DNA recapitulates the natural properties of HBV cccDNA and serves as an authentic model to study cccDNA minichromosomes functionality. IMPORTANCE: HBV remains a major global health burden, with cccDNA serving as the transcriptional template for viral RNAs that sustain persistent infection. The low copy number of cccDNA in the nucleus and the lack of authentic in vitro models hinder its investigation and therapeutic development. Here, we established an M13 phage–derived single-stranded DNA approach to efficiently generate sequence-authentic HBV cccDNA in vitro . Upon transfection, the cccDNA molecules assembled into minichromosomes and were proven to be biologically active, producing viral RNAs more faithfully recapitulating infection-derived transcripts compared to recombinant cccDNA. The system also permits targeted mutagenesis for loss-of-function studies as well as site-specific labeling. These results provide insights into the nucleosome organization and transcriptional characteristics of the HBV cccDNA minichromosome, offering an authentic platform to investigate minichromosome functionality and host-virus interactions.

  • Open Access

    Scalable and sustainable manufacturing of functional DNA nanoassemblies via self-folding circular single-stranded DNA

    by Tingting Zhai, Siwen Liu, Dantong Lei, Ting Song, Rachel Chun-Yee Tam, Mingying Chen, Jialu Zhang, Jiangchao Qian, Chunhai Fan, Honglin Chen, et al.

    Functional DNA nanoassemblies (fDns) hold promise for biomedical and translational applications, but broader deployment is limited by manufacturing barriers that constrain scalability, reproducibility, and stability. Current biosynthetic approaches rely heavily on downstream enzymatic processing and purification, which dominate economic, operational, and environmental costs at scale. Here we report an integrated manufacturing strategy that combines programmed circular single-stranded DNA with bacteriophage-driven biosynthesis to enable direct production of high-quality fDns with minimal post-assembly purification. By reducing reliance on purification as a major bottleneck, this approach delivers topology-enhanced stability, high assembly efficiency, and batch reproducibility, achieving sub-gram laboratory production at ~$6 per milligram while suggesting a pathway toward scalable manufacturing. We demonstrate versatility through 11 distinct fDns, including an aptamer-functionalized construct that neutralizes SARS-CoV-2 pseudovirus and authentic Omicron variants in cellular and animal models. This work provides a cost-effective, scalable manufacturing framework for fDns, advancing their sustainable and reproducible deployment across life-science applications.


  • Open Access

    Functional DNAzyme-Guided Target Identification and Portable Detection of Colorectal Cancer

    by Yu Yan, Hao Zheng, Shenyang Zhao, Lishuang Lin, Qinqin Hu, Jie Liu, Hongzhou Gu

    Rapid discrimination of colorectal cancer (CRC) at the time of tissue sampling remains clinically challenging. Although DNAzyme-based assays enable selective analysis of complex biological samples, their diagnostic translation is constrained by undefined endogenous activators. Here, using an iterative DNAzyme activity-guided isolation strategy that integrates chromatographic fractionation with affinity enrichment, we identified malic enzyme 1 (ME1) as the molecular activator of a DNAzyme newly selected against colorectal cancer tissue lysates. The ME1-triggered catalytic reaction was then translated into a lateral flow format, enabling instrument-free visual detection within 35 min. In clinical specimens, the platform discriminated CRC from low- and high-grade intraepithelial neoplasia with an AUC of 0.98. By defining the molecular basis of DNAzyme activation and coupling it to a portable readout, this work provides a direct route from evolving DNAzyme probes for sensing complex tissues to rapid, near-point-of-care detection of CRC.


  • Open Access

    Author Correction: R-loop-dependent promoter-proximal termination ensures genome stability

    by Congling Xu, Chengyu Li, Jiwei Chen, Yan Xiong, Zhibin Qiao, Pengyu Fan, Conghui Li, Shuangyu Ma, Jin Liu, Aixia Song, et al.


  • Fusing Allosteric Ribozymes with CRISPR‐Cas12a for Efficient Diagnostics of Small Molecule Targets

    by Lichuan Guo, Shu Zhang, Xinyu Du, Mo Zhou, Hongzhou Gu

    The CRISPR‐Cas systems are adopted as powerful molecular tools for not only genetic manipulation but also point‐of‐care diagnostics. However, methods to enable diagnostics of non‐nucleic‐acid targets with these systems are still limited. Herein, by fusing ligand‐dependent allosteric ribozymes with CRISPR‐Cas12a, a derived CRISPR‐Cas system is created for efficient quantitative analysis of non‐nucleic‐acid targets in 1–2 h. On two different small molecules, the system's generality, reliability and accuracy is demonstrated, and show that the well operability of this system can enable high‐throughput detection of a small molecule in blood samples. The system can be further converted to rely on allosteric deoxyribozyme instead of allosteric ribozyme to recognize non‐nucleic‐acid targets and transduce the signal to CRISPR‐Cas12a for amplification, likely making it easier for storage and more consistent in data generation as DNA possess a stability advantage over RNA. This (deoxy)ribozyme‐assisted CRISPR‐Cas12a system anticipates that it can facilitate bioanalysis in various scientific and clinical settings and further drive the development of clinical translation.


  • DNAzyme-based faithful probing and pulldown to identify candidate biomarkers of low abundance

    by Qinqin Hu, Zongxuan Tong, Ayimukedisi Yalikong, Li-Ping Ge, Qiang Shi, Xinyu Du, Pu Wang, Xi-Yu Liu, Wuqiang Zhan, Xia Gao, et al.

    Biomarker discovery is essential for the understanding, diagnosis, targeted therapy and prognosis assessment of malignant diseases. However, it remains a huge challenge due to the lack of sensitive methods to identify disease-specific rare molecules. Here we present MORAC, molecular recognition based on affinity and catalysis, which enables the effective identification of candidate biomarkers with low abundance. MORAC relies on a class of DNAzymes, each cleaving a sole RNA linkage embedded in their DNA chain upon specifically sensing a complex system with no prior knowledge of the system’s molecular content. We show that signal amplification from catalysis ensures the DNAzymes high sensitivity (for target probing); meanwhile, a simple RNA-to-DNA mutation can shut down their RNA cleavage ability and turn them into a pure affinity tool (for target pulldown). Using MORAC, we identify previously unknown, low-abundance candidate biomarkers with clear clinical value, including apolipoprotein L6 in breast cancer and seryl-tRNA synthetase 1 in polyps preceding colon cancer.